Clinicopathological Characteristics and Outcome of Cytophagic Histiocytic Panniculitis: A Single-Center, Retrospective Study
DOI: https://doi.org/10.2147/ccid.s460784
2024-05-30
Clinical Cosmetic and Investigational Dermatology
Abstract:Ting Su, Wentong Wang, Xixi Xiong, Meihua Zhang, Yan Lu, &ast Zhonglan Su &ast Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Lu; Zhonglan Su, Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, People's Republic of China, Email ; Background: Cytophagic histiocytic panniculitis (CHP) is a rare panniculitis associated with systemic features characterized by the infiltration of subcutaneous adipose tissue by benign-appearing T lymphocytes and phagocytic histiocytes, mimicking hemophagocytic lymphohistiocytosis (HLH) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Purpose: To establish the clinicopathological features and response to treatment of CHP and evaluate the prognosis of patients and guide therapy based on the current state of knowledge. Material and Methods: Clinical, laboratory, histopathological, and outcome data of 12 patients with CHP were retrospectively collected between 2009 and 2022. Results: All the patients presented with plaques or nodules, mostly located in the lower extremities (11/12). Fewer cases involved systemic symptoms (9/12) and laboratory abnormalities (6/12), and none were positive for serum Epstein-Barr virus (EBV)-DNA. Histopathological examination revealed mixed septal and lobular inflammatory infiltration of histiocytes and lymphocytes. Large or atypical lymphocytes were rarely present (2/12). In some patients, varying proportions of plasma cells, neutrophils, and eosinophils were observed. The extent of histocytophagy was mild (9/12), moderate (2/12), and severe (1/12). HLH was not observed in any of our cases, none of which were fatal. Conclusion: The uniqueness of our study lies in the presence of neutrophil-rich dermal and subcutaneous infiltrates, associated with connective tissue disorders (CTD) and streptococcal infections. Our study reveals that EBV-negative CHP tends to a better prognosis than previously research, filling the gap in the much-needed details of CHP in the Chinese population. Moreover, CHP may present as a reactive process in combined primary diseases; further studies are required to validate these findings. Plain Language Summary: Cytophagic histiocytic panniculitis (CHP) is a rare panniculitis associated with systemic features characterized by the infiltration of subcutaneous adipose tissue by benign-appearing T lymphocytes and phagocytic histiocytes, also may be present in hemophagocytic lymphohistiocytosis and subcutaneous panniculitis-like T-cell lymphoma. The presence of neutrophil-rich dermal and subcutaneous infiltrates, associated with connective tissue disorders and streptococcal infections. In addition, EBV-negative CHP has a better prognosis than previously thought and provides knowledge of its prognosis in the Chinese population. With changes in the disease pedigree supported by the development of medical technology, CHP may present as a reactive process of a combined primary disease. Keywords: Cytophagic histiocytic panniculitis, Epstein-Barr virus, hemophagocytic lymphohistiocytosis, retrospective study Cytophagic histiocytic panniculitis (CHP) is a rare panniculitis associated with systemic features, including fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, hepatic abnormalities, hypertriglyceridemia, and coagulopathy. 1 CHP may be an isolated skin disorder, associated with other conditions, such as connective tissue disorders (CTD), infections, and malignancies. Histologically, it is characterized by the infiltration of subcutaneous adipose tissue by benign-appearing T lymphocytes and phagocytic histiocytes ("bean bag cells"), 2 which has also been identified as a typical manifestation of hemophagocytic lymphohistiocytosis (HLH) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL). HLH is a life-threatening condition characterized by uncontrolled activation and proliferation of T cells, resulting in hypercytokinemia, proliferation of histiocytes, and hemophagocytosis. 3 SPTCL is a rare primary cutaneous lymphoma of mature cytotoxic T cells that simulates panniculitis and is often complicated by HLH. Patients with CHP may have different clinical courses depending mainly on their isolated presentation or association with HLH. 3 Some patients progress rapidly and often die within one year, due to sepsis, coagulation disorders, and multi-organ failure. 1 Other patients experience recurrent bouts of reactivation and may survive for years. 3 CHP re -Abstract Truncated-
dermatology